Advanced liver cancer complicated with portal vein tumor thrombus
Conditions
Interventions
CLAPT group:CLAPT surgery + lenvatinib
TACE group:TACE+lenvatinib
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. First confirmed advanced HCC with portal vein thrombus formation (Cheng's type ? PVTT); 3. The physical state of the eastern Tumor cooperative group (ECOG) was 0 or 1; 4. Normal liver, FLR/SLV < 30% or GRWR<0.5% by imaging examination; Abnormal liver due to obstructive jaundice, severe fatty liver, hepatitis, chemotherapy, etc., FLR/SLV < 40% or GRWR<0.8%; 5. No coagulation disorder; 6. No extrahepatic primary malignant tumor or metastasis.
Exclusion criteria
Exclusion criteria: 1. Other concurrent serious medical conditions, such as underlying heart or kidney disease, infectious diseases; 2. Pregnant and lactating patients; 3. Systemic chemotherapy and other chemotherapy treatments; 4. History of gastrointestinal bleeding within 2 weeks of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year overall survival ;2-year progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication rates within 30 days after surgery;Mortality within 90 days after surgery; | — |
Countries
China
Contacts
Public ContactWen Zhang
Outcome results
None listed